Developing new therapies for people with rare muscle disorders.
Edgewise is committed to developing new therapies for people living with rare muscle disorders. Novel therapies require years of laboratory research and clinical testing to evaluate safety and efficacy. Volunteers who enroll in clinical trials help Edgewise evaluate the potential benefits and safety profile of these investigational therapies in humans. Additionally, investigational therapies must successfully progress through various phases of clinical research before they can be approved for use in the clinical setting.
Please visit the links below to learn more about our active clinical trials and see if you qualify to participate. By taking part in one of our clinical trials, you can help us make a difference for the entire community of people living with rare muscle disorders.
Edgewise Clinical Trials
ARCH, a Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy
CANYON, a Phase 2 Study of EDG-5506 in Individuals with Becker Muscular Dystrophy
LYNX, a Phase 2 Study of EDG-5506 in Children with Duchenne Muscular Dystrophy
Defining Endpoints in Becker Muscular Dystrophy
A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults
For more information about our trials, email firstname.lastname@example.org.